PNC Financial Services Group’s Halozyme HALO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$1.14M Buy
14,582
+2,722
+23% +$186K ﹤0.01% 1317
2026
Q1
$767K Buy
11,860
+1,635
+16% +$115K ﹤0.01% 1430
2025
Q4
$688K Sell
10,225
-136
-1% -$9.15K ﹤0.01% 1454
2025
Q3
$760K Buy
10,361
+504
+5% +$33.5K ﹤0.01% 1395
2025
Q2
$513K Buy
9,857
+727
+8% +$41.4K ﹤0.01% 1543
2025
Q1
$583K Sell
9,130
-578
-6% -$33.6K ﹤0.01% 1417
2024
Q4
$464K Sell
9,708
-353
-4% -$18.1K ﹤0.01% 1592
2024
Q3
$576K Sell
10,061
-1,555
-13% -$89.1K ﹤0.01% 1441
2024
Q2
$608K Buy
11,616
+131
+1% +$5.75K ﹤0.01% 1382
2024
Q1
$467K Buy
11,485
+121
+1% +$4.54K ﹤0.01% 1578
2023
Q4
$420K Sell
11,364
-499
-4% -$18.8K ﹤0.01% 1633
2023
Q3
$453K Sell
11,863
-784
-6% -$32.1K ﹤0.01% 1547
2023
Q2
$456K Buy
12,647
+34
+0.3% +$1.16K ﹤0.01% 1626
2023
Q1
$482K Sell
12,613
-2,078
-14% -$97.5K ﹤0.01% 1564
2022
Q4
$836K Sell
14,691
-3,113
-17% -$159K ﹤0.01% 1227
2022
Q3
$705K Buy
17,804
+673
+4% +$29.7K ﹤0.01% 1311
2022
Q2
$753K Buy
17,131
+305
+2% +$13.2K ﹤0.01% 1309
2022
Q1
$671K Buy
16,826
+4,066
+32% +$145K ﹤0.01% 1461
2021
Q4
$513K Sell
12,760
-9,229
-42% -$345K ﹤0.01% 1677
2021
Q3
$894K Buy
21,989
+4,609
+27% +$193K ﹤0.01% 1257
2021
Q2
$789K Sell
17,380
-925
-5% -$40.9K ﹤0.01% 1330
2021
Q1
$763K Buy
18,305
+2,694
+17% +$123K ﹤0.01% 1301
2020
Q4
$667K Sell
15,611
-23,157
-60% -$832K ﹤0.01% 1311
2020
Q3
$1.02M Buy
38,768
+109
+0.3% +$3.04K ﹤0.01% 1042
2020
Q2
$1.04M Sell
38,659
-6,028
-13% -$136K ﹤0.01% 1026
2020
Q1
$804K Buy
44,687
+6,025
+16% +$114K ﹤0.01% 1060
2019
Q4
$686K Sell
38,662
-328
-0.8% -$5.68K ﹤0.01% 1291
2019
Q3
$604K Buy
38,990
+87
+0.2% +$1.43K ﹤0.01% 1505
2019
Q2
$668K Buy
38,903
+200
+0.5% +$3.23K ﹤0.01% 1466
2019
Q1
$624K Buy
38,703
+9
+0% +$146 ﹤0.01% 1525
2018
Q4
$565K Hold
38,694
﹤0.01% 1491
2018
Q3
$702K Hold
38,694
﹤0.01% 1491
2018
Q2
$652K Sell
38,694
-6
-0% -$113 ﹤0.01% 1496
2018
Q1
$759K Sell
38,700
-994
-3% -$19.3K ﹤0.01% 1435
2017
Q4
$803K Buy
39,694
+38,694
+3,869% +$711K ﹤0.01% 1422
2017
Q3
$17K Hold
1,000
﹤0.01% 3459
2017
Q2
$13K Hold
1,000
﹤0.01% 3489
2017
Q1
$13K Buy
+1,000
New +$12.6K ﹤0.01% 3441
2016
Q3
Sell
-549
Closed -$5K 4105
2016
Q2
$5K Sell
549
-21
-4% -$207 ﹤0.01% 3838
2016
Q1
$5K Sell
570
-38,889
-99% -$366K ﹤0.01% 3840
2015
Q4
$683K Buy
39,459
+6,291
+19% +$100K ﹤0.01% 1364
2015
Q3
$445K Sell
33,168
-12,426
-27% -$249K ﹤0.01% 1632
2015
Q2
$1.03M Buy
45,594
+4,195
+10% +$73.7K ﹤0.01% 1257
2015
Q1
$590K Buy
41,399
+1,801
+5% +$26K ﹤0.01% 1537
2014
Q4
$382K Buy
39,598
+1,874
+5% +$16.6K ﹤0.01% 1687
2014
Q3
$344K Sell
37,724
-28,298
-43% -$270K ﹤0.01% 1680
2014
Q2
$652K Buy
66,022
+65,732
+22,666% +$558K ﹤0.01% 1282
2014
Q1
$4K Buy
+290
New +$4.3K ﹤0.01% 3294

Other funds holding HALO

PNC Financial Services Group's HALO Position: Q2 2026 in Review

PNC Financial Services Group increased its Halozyme (HALO) stake by 23% in Q2 2026, buying an estimated $186K and bringing the position to 14,582 shares worth $1.14M. The position accounts for ﹤0.01% of the portfolio, ranked #1317.

PNC Financial Services Group first reported a position in HALO in Q1 2014 and has held it in 48 quarters since. 342 funds tracked by Wall St. Rank hold HALO as of Q2 2026.

  • PNC Financial Services Group held 14,582 shares of Halozyme worth $1.14M as of Q2 2026.
  • PNC Financial Services Group bought 2,722 Halozyme shares in Q2 2026, an estimated $186K.
  • Halozyme made up ﹤0.01% of PNC Financial Services Group's portfolio in Q2 2026, its #1317 holding.
  • PNC Financial Services Group first reported a position in Halozyme in Q1 2014 and has held it in 48 quarters since.
  • 342 funds tracked by Wall St. Rank held Halozyme as of Q2 2026.

Based on PNC Financial Services Group's 13F filing for Q2 2026, filed 7 Aug 2026.